3-37001053-G-C
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_000249.4(MLH1):c.306G>C(p.Glu102Asp) variant causes a missense, splice region change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely pathogenic in Lovd. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E102A) has been classified as Pathogenic.
Frequency
Consequence
NM_000249.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 26
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Jul 12, 2023 | This variant is considered likely pathogenic. mRNA analysis has demonstrated abnormal mRNA splicing occurs [PMID: 22736432, Myriad internal data]. - |
Lynch syndrome Pathogenic:1
Pathogenic, reviewed by expert panel | research | International Society for Gastrointestinal Hereditary Tumours (InSiGHT) | Sep 05, 2013 | Variant causing splicing aberration predicted to interrupt known functional domains: full inactivation of variant allele - |
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 17, 2023 | This sequence change affects codon 102 of the MLH1 mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the MLH1 protein. RNA analysis indicates that this variant induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with clinical features of Lynch syndrome (PMID: 22736432). ClinVar contains an entry for this variant (Variation ID: 90150). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of 3, but is expected to preserve the integrity of the reading-frame (PMID: 22736432). This variant disrupts a region of the MLH1 protein in which other variant(s) (p.Thr82Ala) have been determined to be pathogenic (PMID: 10422993, 17510385, 19690142, 20587412, 21239990, 21404117, 22736432, 23403630, 26300997, 28514183). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 07, 2022 | The c.306G>C pathogenic mutation (also known as p.E102D), located in coding exon 3 of the MLH1 gene, results from a G to C substitution at nucleotide position 306. The amino acid change results in glutamic acid to aspartic acid at codon 102, an amino acid with highly similar properties. However, this change occurs in the last base pair of coding exon 3, which makes it likely to have some effect on normal mRNA splicing. In one study, this alteration, which was also detected with a MLH1 variant with no predicted effect on splicing (c.248G>T), demonstrated in-frame exon 3 skipping upon RT-PCR analysis using patient RNA and no full-length transcript was expressed by the variant allele (Borràs E et al. Hum. Mutat., 2012 Nov;33:1576-88). Another alteration at the same nucleotide position, c.306G>A, which also results in exon 3 skipping, has been classified as pathogenic based on identification in individuals with constitutional mismatch repair deficiency syndrome and Lynch syndrome (Ambry internal data; external communication with outside laboratory). In a functional study, MLH1 p.E102D demonstrated reduced mismatch repair activity (56%) compared to wild type MLH1 (79.7%) in a complementation assay using a human colon cancer cell line, but relative MLH1 protein expression was >75% in the same cell line upon transient expression (Takahashi et al. Cancer Res. 2007. 67(10): 4595-4604). RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at